Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany

Ziller V Schüssel K Czeche S Franzmann A Klöckner D Quinzler R Schulz M Möhrke W Hadji P

ECCEO 9-IOF, 18. - 21.03.2009, Athens, Greece.
Osteoporosis Int. 2009; 20 (Suppl. 1): S112 (Abstract P320).

Conflicts of interests: The DAPI received financial support for this study from Procter and Gamble Pharmaceuticals; Moehrke W. employee Procter and Gamble Pharmaceuticals; Hadji P. consultant for Procter and Gamble Pharmaceuticals.

Impact of risk communications and market withdrawals on prescribing of cyclooxygenase-2 inhibitors and non-selective nonsteroidal anti-inflammatory drugs

Aktuelle Verordnungen von COX-2-Hemmern in Deutschland

Persistence under treatment with ramipril

Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany

Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany

Beeinflusst die Umstellung von Risedronat oder Alendronat Originalprodukten auf Generika die Compliance (Persistenz)?

Persistence with basal supported oral therapy - comparison of insulin glargine versus NPH insulin.